Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype. Read more about Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype.
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update. Read more about Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.
Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers". Read more about Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers".
Network medicine in disease analysis and therapeutics. Read more about Network medicine in disease analysis and therapeutics.
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Read more about CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
Profiling solute carrier transporters in the human blood-brain barrier. Read more about Profiling solute carrier transporters in the human blood-brain barrier.
Genetic and pharmacokinetic determinants of response to transdermal nicotine in white, black, and Asian nonsmokers. Read more about Genetic and pharmacokinetic determinants of response to transdermal nicotine in white, black, and Asian nonsmokers.
Association of CYP2C9*2 with bosentan-induced liver injury. Read more about Association of CYP2C9*2 with bosentan-induced liver injury.
Transporters in drug development and clinical pharmacology. Read more about Transporters in drug development and clinical pharmacology.
